Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Overexpression of NSAID-activated gene product in prostate cancer. Int J Surg Pathol 2003 Jul;11(3):159-66

Date

08/02/2003

Pubmed ID

12894347

DOI

10.1177/106689690301100302

Scopus ID

2-s2.0-0043246661   16 Citations

Abstract

NSAID-activated gene (NAG-1) protein was previously identified by microarray analysis as overexpressed in prostate cancer. We performed immunohistochemistry and Western blotting with rabbit polyclonal antibody to NAG-1. Fifty malignant tissues obtained by prostatectomy and 17 from benign cases were compiled. Cancer tissues included Gleason scores 3-6, 3+4=7, 4+3=7, and 8-10. Cancer and high-grade prostatic intraepithelial neoplasia (PIN) consistently showed moderate to intense cytoplasmic reactivity in 95-100% of epithelium. Staining intensity inversely correlated with preoperative serum prostate-specific antigen (PSA) (p=0.005) and with grade, averaging (on a 0 to 3+ scale) 2.3 +/- 0.6 in the lowest grade group, and 2.0 +/- 0.7, 1.8 +/- 0.5, and 1.5 +/- 0.6 as grade increased (p<0.008). Benign epithelium was nonreactive in 17/17 specimens without concurrent cancer (11 transurethral resection, 2 enucleation, 4 biopsy, p=0.002). Decreased NAG-1 expression in higher grade cancer is consistent with its known antitumorigenic, proapoptotic activities.

Author List

Iczkowski KA, Pantazis CG

Author

Kenneth A. Iczkowski MD Professor in the Pathology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Biomarkers, Tumor
Blotting, Western
Cytokines
Epithelium
Growth Differentiation Factor 15
Humans
Immunohistochemistry
Male
Prostate
Prostate-Specific Antigen
Prostatic Intraepithelial Neoplasia
Prostatic Neoplasms
jenkins-FCD Prod-398 336d56a365602aa89dcc112f077233607d6a5abc